Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 365-374

  Kestell, Philip ^a   Pruijn, Frederik B ^a   Siim, Bronwyn G ^a   Palmer, Brian D ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bioreductive drugs; CB 1954; Drug metabolism; Enzyme prodrug therapy; SN 23862

Indexed keywords

1 (2 CHLOROETHYL) 6 NITRO 1,2,3,4 TETRAHYDROQUINOXALINE 7 CARBOXAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 [N (2 CHLOROETHYL)AMINO] 2,4 DINITROBENZAMIDE; 5 [N,N BIS(2 CHLOROETHYL)AMINO] 2 AMINO 4 NITROBENZAMIDE; 5 [N,N BIS(2 CHLOROETHYL)AMINO] 2,4 DINITROBENZAMIDE; 5 [N,N BIS(2 CHLOROETHYL)AMINO] 2,4 DINITROBENZOIC ACID; 5 [N,N BIS(2 HYDROXYETHYL)AMINO] 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; CB 10 150; CB 10 236; CB 7060; SN 23862; SN 23863; SN 23919; SN 24939; SN 25087; SN 25574; SN 25575; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG OXIDATION; DRUG URINE LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANILINE MUSTARD; ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; PRODRUGS;

EID: 0033729429     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000165     Document Type: Article

References (44)

1. High performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma
2. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase
3. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy
4. Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione
5. Hypoxia specific cytotoxins in cancer therapy
6. Identification of the major hypoxic metabolites of CB 1954 and its nitrogen mustard analogue, SN 23862, in Chinese hamster cells
7. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
8. Metabolism of aniline mustard [N,N]-di(2-chloroethyl)aniline
9. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells
10. Bioreducible mustards a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)
11. Recent developments in the design of bioreductive drugs
12. In vitro degradation of L-phenylalanine mustard (L-PAM)
13. Metabolism of nitromide in the rat. II. Sites of nitro-reduction
14. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene
15. MKMODEL, a modelling tool for microcomputers - A pharmacokinetic evaluation and comparison with standard computer programs
16. The metabolism of the anti-tumour agent 5-(l-aziridinyl)-2,4-dinitrobenzamide (CB 1954)
17. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-l-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
18. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-l-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
19. Bio-activation of CB 1954: Reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species
20. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an Eschericia coli nitroreductase and Walker DT diaphorase
21. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
22. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy
23. Toxicity profile of chloroacetaldehyde
24. A 13C NMR study of 1-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolate perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism
25. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
26. Antibody-directed enzyme prodrug therapy (ADEPT)
27. Hydrolysis of ester- and amide-type drugs by the purified isoenzymes of non-specific carboxylesterase from rat liver
28. Metabolic disposition of chlorambucil in rats
29. Metabolism and excretion of dinitrobenzenes by male Fischer-344 rats
30. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines
31. Hypoxiaselective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells
32. Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide
33. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862)
34. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide
35. Bioreductive therapies: An overview of drugs and their mechanisms of action
36. Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3-(methylcarbamoyl)triazenes: Formation of chloroacetaldehyde and relevance to biological activity
37. Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat
38. Nitro reduction as an electronic switch for bioreductive drug activation
39. New colorimetric cytotoxicity assay for anticancer-drug screening
40. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo
41. Bioreductive drugs into the next millenium
42. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069
43. CB 1954 revisited. I. Disposition kinetics and metabolism